Literature DB >> 22873778

DTPa-HBV-IPV/Hib vaccine (Infanrix hexa™): a guide to its use in infants.

Katherine A Lyseng-Williamson1, Sohita Dhillon.   

Abstract

Infanrix hexa™, a diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliomyelitis, and Haemophilus influenzae type b (Hib) conjugate vaccine, is indicated for primary and booster vaccination of infants. Available clinical data from more than a decade of experience with the vaccine indicate that primary and booster vaccination with Infanrix hexa™ is a safe and useful option for providing protection against the common childhood diseases of diphtheria, tetanus, poliomyelitis, pertussis, hepatitis B, and disease caused by Hib.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22873778     DOI： 10.2165/11210000-000000000-00000

Source DB:  PubMed          Journal:  Paediatr Drugs        ISSN： 1174-5878            Impact factor:   3.022


  41 in total

1.  WHO position paper on Haemophilus influenzae type b conjugate vaccines. (Replaces WHO position paper on Hib vaccines previously published in the Weekly Epidemiological Record.

Authors: 
Journal:  Wkly Epidemiol Rec       Date:  2006-11-24

2.  The use of combination vaccines has improved timeliness of vaccination in children.

Authors:  Helen Kalies; Veit Grote; Thomas Verstraeten; Luc Hessel; Heinz-Josef Schmitt; Rüdiger von Kries
Journal:  Pediatr Infect Dis J       Date:  2006-06       Impact factor: 2.129

Review 3.  Review of 8 years of experience with Infanrix hexa (DTPa-HBV-IPV/Hib hexavalent vaccine).

Authors:  Fred Zepp; Heinz-Josef Schmitt; Jan Cleerbout; Thomas Verstraeten; Lode Schuerman; Jeanne-Marie Jacquet
Journal:  Expert Rev Vaccines       Date:  2009-06       Impact factor: 5.217

4.  Immunogenicity and reactogenicity of a novel hexavalent DTPa-HBV-IPV/Hib vaccine compared to separate concomitant injections of DTPa-IPV/Hib and HBV vaccines, when administered according to a 3, 5 and 11 month vaccination schedule.

Authors:  Mária Avdicová; Viktor Prikazský; Henrieta Hudecková; Lode Schuerman; Paul Willems
Journal:  Eur J Pediatr       Date:  2002-10-05       Impact factor: 3.183

5.  Long-term follow-up of Swedish children vaccinated with acellular pertussis vaccines at 3, 5, and 12 months of age indicates the need for a booster dose at 5 to 7 years of age.

Authors:  Lennart Gustafsson; Luc Hessel; Jann Storsaeter; Patrick Olin
Journal:  Pediatrics       Date:  2006-09       Impact factor: 7.124

6.  Immunogenicity and reactogenicity of a three-dose primary vaccination course with a combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-haemophilus influenzae type b vaccine coadministered with a meningococcal C conjugate vaccine.

Authors:  Juan C Tejedor; Félix Omeñaca; José García-Sicilia; Joaquim Verdaguer; Diego Van Esso; Carlos Esporrín; Vicente Molina; Marta Muro; Josep Marés; Manuel Enrubia; Fernando Moraga; Pilar García-Corbeira; Kurt Dobbelaere; Lode Schuerman
Journal:  Pediatr Infect Dis J       Date:  2004-12       Impact factor: 2.129

7.  Safety, reactogenicity and immunogenicity of a combined hexavalent tetanus, diphtheria, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate vaccine, for primary immunization of infants.

Authors:  F Zepp; M Knuf; U Heininger; K Jahn; A Collard; P Habermehl; L Schuerman; R Sänger
Journal:  Vaccine       Date:  2004-06-02       Impact factor: 3.641

8.  Evaluation of the immunogenicity and reactogenicity of a DTPa-HBV-IPV Combination vaccine co-administered with a Hib conjugate vaccine either as a single injection of a hexavalent combination or as two separate injections at 3, 5 and 11 months of age.

Authors:  Giovanni Gabutti; Fred Zepp; Lode Schuerman; Pietro Dentico; Francesco Bamfi; Renato Soncini; Peter Habermehl; Markus Knuf; Pietro Crovari
Journal:  Scand J Infect Dis       Date:  2004

9.  Antibody persistence and booster vaccination during the second and fifth years of life in a cohort of children who were born prematurely.

Authors:  Félix Omeñaca; José Garcia-Sicilia; Reyes Boceta; Alessandra Sistiaga-Hernando; Pilar García-Corbeira
Journal:  Pediatr Infect Dis J       Date:  2007-09       Impact factor: 2.129

10.  Immunogenicity and safety of a tetravalent measles-mumps-rubella-varicella vaccine co-administered with a booster dose of a combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine in healthy children aged 12-23 months.

Authors:  Fred Zepp; Ulrich Behre; Klaus Kindler; Karl-Heinz Laakmann; Heidemarie Pankow-Culot; Wilma Mannhardt-Laakmann; François Beckers; Dominique Descamps; Paul Willems
Journal:  Eur J Pediatr       Date:  2007-05-31       Impact factor: 3.860
View more
  2 in total

Review 1.  The value of childhood combination vaccines: From beliefs to evidence.

Authors:  Khaled Maman; York Zöllner; Donato Greco; Gerard Duru; Semukaya Sendyona; Vanessa Remy
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 2.  Induced immunity against hepatitis B virus.

Authors:  Zeinab Nabil Ahmed Said; Kouka Saadeldin Abdelwahab
Journal:  World J Hepatol       Date:  2015-06-28
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.